South Africa
Key Insights
- 1
No psychedelic therapy is approved for routine care; South Africans can access esketamine only under strict prescription controls, while psilocybin remains unscheduled for treatment.
- 2
The database shows 6 trials, 0 active, and only 2 compounds studied: esketamine and placebo, signalling a tiny, ketamine-led evidence base.
- 3
South Africa’s first notable global footprint is ketamine research: the country sits on the front line of peri-operative and depression use, but psychiatric data remain sparse.
- 4
Momentum hinges on regulatory clarity rather than pipeline depth: SAHPRA now has a published esketamine PI, and trial governance sits with its clinical-trials unit.
Reimbursed Care Access
South Africa maintains a restrictive, medically‑regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off‑label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels. Most classical serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X) and sacramental preparations (ayahuasca) remain controlled with no routine reimbursed medical availability outside authorised research or tightly regulated exemptions. Ibogaine is used in some private/clinic contexts but carries legal and safety controversy and is effectively available only in specialised private settings or legal gray areas, not as a reimbursed public therapy.
Quick Indicators
Organizations
1Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in South Africa.